Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform

Allay Therapeutics完成6000万美元超额认购融资,推进超持续疼痛平台

2021-09-15 19:30:08 BioSpace

本文共1529个字,阅读需4分钟

Financing led by Arboretum Ventures. Managing Partner Nicole J. Walker to join Allay Therapeutics Board of Directors ATX-101 to advance to Phase 2b development in total knee replacement surgeries in 2021 Financing will also support broader development of ATX platform for ultra-sustained pain relief MENLO PARK, Calif.--(BUSINESS WIRE)-- Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the completion of its oversubscribed $60M Series C financing, led by Arboretum Ventures. Participating in the round were NEA, Temasek, Pavilion Capital, Brandon Capital Partners, Vertex Growth, Vertex Ventures HC and WTT Investment Ltd. The proceeds from the Series C will advance the Company’s lead candidate, ATX-101, into Phase 2b clinical trials, and support the further development of Allay’s platform for ultra-sustained analgesic products. “We’re pleased to attract such an impressive syndicate of healthcare investors to this round, and we’re fortunate to partner with Nicole and the Arboretum Ventures team to advance the Allay platform of products through clinical development. The vote of confidence by these investors is gratifying as we pursue our goal of allaying patients’ fears of extended painful recoveries and reliance on opioids after surgery,” said Adam Gridley, Chief Executive Officer of Allay Therapeutics. “We share a common belief that our underlying platform of tunable product candidates will change the way that patients, physicians and payors manage pain and will reduce costs to the overall healthcare system.” Allay intends to proceed into a Phase 2b study of ATX-101 in total knee arthroplasties (TKA, also called total knee replacements) in the United States. Beyond ATX-101, Allay’s R&D teams in Singapore and the Bay Area have developed proof-of-concept of new implant variants, injectable formulations, formulations to permit patient self-dosing ‘on demand’ and formulations that incorporate a variety of small molecules and other local analgesics. The Company intends to advance at least one new clinical candidate into clinical trials each year and is currently building out its manufacturing capabilities in the Bay Area to support future product launches. “Demand for total knee replacement surgery is growing dramatically, and with it, desire for non-opioid solutions providing lasting pain relief. We believe that Allay’s technology platform offers unprecedented potential breadth in terms of applicability and therapeutic profile for pain management, an area in need of innovation,” said Nicole J. Walker, Managing Partner, Arboretum Ventures. “Allay combines strong science, a veteran team and a clear vision for advancing an array of new products.” About Allay Therapeutics Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. Our proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available. Our platform and vision were shaped by The Foundry incubator and Lightstone Venture’s Singapore Fund. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore. Learn more at allaytx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005154/en/ Investors Adam Gridley adam.gridley@allaytx.com Media Chris Railey chris@tenbridgecommunications.com M: +1 617-834-0936 Source: Allay Therapeutics View this news release online at: http://www.businesswire.com/news/home/20210915005154/en
由植物园风险投资公司牵头的融资。执行合伙人妮可·J·沃克加入Allay Therapeutics董事会 2021年ATX-101全膝关节置换手术将进入2B阶段 融资还将支持ATX平台的更广泛发展,用于超持续止痛 加州门洛帕克--(商业网)--Allay Therapeutics是一家临床阶段生物技术公司,开创了超持续止痛产品,以改变术后疼痛管理和康复,今天宣布完成其超额认购的6000万美元C轮融资,由Arboretum Ventures牵头。参与此次研究的有NEA、淡马锡、Pavilion Capital、Brandon Capital Partners、Vertex Growting、Vertex Ventures HC和WTT Investment Ltd.。C系列的收益将推动公司的主要候选产品ATX-101进入2B期临床试验,并支持Allay超持续镇痛产品平台的进一步发展。 “我们很高兴能吸引如此令人印象深刻的医疗保健投资者辛迪加加入这一轮,我们很幸运能与妮可和植物园风险投资团队合作,通过临床开发推进产品的Allay平台。Allay Therapeutics首席执行官亚当·格里德利(Adam Gridley)表示:“这些投资者的信任投票令人欣慰,因为我们追求减轻患者对术后长期痛苦康复和对阿片类药物依赖的担忧的目标。”“我们有一个共同的信念,即我们的潜在可调产品候选平台将改变患者、医生和支付者管理疼痛的方式,并将降低整个医疗保健系统的成本。” Allay打算在美国进行ATX-101在全膝关节成形术(TKA,也称为全膝关节置换术)中的2B期研究。除了ATX-101,Allay在新加坡和海湾地区的研发团队还开发了新植入体变体的概念验证、注射配方、允许患者“按需”自我给药的配方以及包含各种小分子和其他局部镇痛药的配方。该公司打算每年至少推进一个新的临床候选项目进入临床试验,目前正在湾区建设其制造能力,以支持未来的产品上市。 “对全膝关节置换手术的需求正在急剧增长,随之而来的是对提供持久疼痛缓解的非阿片类解决方案的渴望。我们相信Allay的技术平台在疼痛管理的适用性和治疗方面提供了前所未有的潜在广度,疼痛管理是一个需要创新的领域,“植物园风险投资公司管理合伙人Nicole J.Walker说。“Allay结合了强大的科学、经验丰富的团队和推进一系列新产品的清晰愿景。” 关于减轻疗法 Allay Therapeutics是开创性的超持续镇痛产品,以改变术后疼痛管理和病人和医生的恢复。我们的专有技术平台将经过验证的非阿片类止痛药和生物聚合物结合在一起,创造出可溶解的候选药物,在目标部位持续数周时间内提供疼痛缓解:比目前可用的最持久的疼痛治疗高出一个数量级。我们的平台和愿景是由铸造孵化器和Lightstone Venture的新加坡基金塑造的。Allay将旧金山湾区和新加坡的企业家、科学家、临床医生和创新者组成一个充满活力的全球团队。在allaytx.com了解更多信息。 在businesswire.com查看源代码版本:https://www.businesswire.com/news/home/20210915005154/en/ 投资者 亚当·格里德利 adam.gridley@allaytx.com 媒体 克里斯·拉伊利 @tenbridgecommunications.com M:+1 617-834-0936 来源:Allay Therapeutics 在网上查看此新闻稿: http://www.businesswire.com/news/home/20210915005154/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文